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Determination of oestrogen receptor alpha (ER) represents at present the most important predictive factor in breast cancers. Data of
ours and of other authors suggest that promising predictive/prognostic factors may also include pS2, metallothionein (MT) and CD24.
Present study aimed at determining prognostic and predictive value of immunohistochemical determination of ER, pS2, MT, and
CD24 expression in sections originating from 104 patients with breast cancer. An univariate and multivariate analysis was performed.
Both univariate and multivariate analyses demonstrated that cytoplasmic-membranous expression of CD24 (CD24c-m) represents a
strong unfavourable prognostic factor in the entire group and in most of the subgroups of patients. In several subgroups of the
patients also a prognostic value was demonstrated of elevated expression of pS2 and of membranous expression of CD24. Our
studies demonstrated that all patients with good prognostic factors (higher ER and pS2 expressions, lower MT expression, CD24c-m
negativity) survived total period of observation (103 months). The study documented that cytoplasmic-membranous expression of
CD24 represented an extremely strong unfavourable prognostic factor in breast cancer. Examination of the entire panel of the
studied proteins permitted to select a group of patients of an exceptionally good prognosis.
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In the entire world, breast cancer represents the most frequent
female malignant tumour. In 2002, 1151298 new cases of breast
cancer were diagnosed and 410712 deaths due to the disease were
noted (Jemal et al, 2002). The principal therapeutic approach in
breast cancer involves surgery. In advanced cases supplementary
therapy is needed, involving pharmacotherapy and/or radio-
therapy. Considering that breast cancer is a hormone-related
tumour, cases of tumour with oestrogen receptor alpha (ER), or
around 60% of breast cancer cases in postmenopausal women are
treated with a drug of antioestrogenic activity, tamoxifen. Also
other methods of hormonal treatment are in use, including
aromatase inhibitors, analogues of GnRH, etc. In advanced cases of
breast cancer, in cases of a more aggressive course or in cases
insensitive to hormonal therapy chemotherapy is used (Goldhirsch
et al, 1998; National Institutes of Health Consensus Development
Panel, 2001; Mori et al, 2002). As the hormonal treatment, as
compared to chemotherapy, is much better tolerated by the
patients the capacity to predict clinical response to tamoxifen and
clinical course of the tumour becomes a significant aim in the
diagnosis.
In ER-positive cases, clinical response to tamoxifen treatment
used to be obtained in only around 60% patients (Goldhirsch et al,
1998). Therefore, additional exponents of tamoxifen sensitivity/
resistance and variables typical for breast cancer cases of a more
aggressive course are searched for. Numerous studies have been
focused on oestrogen-dependent proteins, that is, the proteins with
ER-controlled expression. Coexpression of ER and of progesteron
receptor was found to be typical for cases of a slower course and
more sensitive to tamoxifen (Fitzgibbons et al, 2000). Another
oestrogen-dependent protein involves pS2 (Nunez et al, 1987).
However, data on prognostic value of the protein are equivocal and
the problem requires further studies (Fitzgibbons et al, 2000;
Surowiak et al, 2001). In our earlier studies, performed on a group
of 60 patients with ductal breast cancer, postoperatively treated
with tamoxifen, expression of metallothionein (MT), which is
downregulated by ER was found to be an unfavourable prognostic
factor (Surowiak et al, 2005b). In the same group of patients
cytoplasmic/membraneous expression of CD24, which is also
downregulated by ER, proved to be typical for cases with shorter
overall survival time (Surowiak et al, 2006).
Prognostic and predictive value of novel unfavourable prog-
nostic and predictive factors in breast cancer should be
corroborated on a larger group of patients and should be
compared to the significance of expression of the most important
prognostic protein in the tumour, the oestrogen receptor. In order
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also a multivariate analysis should be performed.
In this study, using univariate and multivariate analyses,
prognostic and predictive values were estimated of immuno-
histochemical tests of ER, pS2, MT and CD24 expression in an
unselected group of 104 patients with ductal breast cancer.
MATERIALS AND METHODS
Patients
Immunohistochemical analysis was performed retrospectively on
tissue samples that were taken for routine diagnostic purposes.
The cases were selected based on availability of tissue and were not
stratified for known preoperative or pathological prognostic
factors. The study was approved by an Institutional Review Board
(IRB) and the patients gave their informed consent before their
inclusion to the study. The total of 104 patients with primary
invasive breast cancer, who were diagnosed in the years 1993–1994
in Lower Silesian Centre of Oncology in Wrocław, Poland, were
qualified to the studies. All the patients were subjected to
mastectomy and, then, were treated with radiotherapy and/or
chemotherapy and/or hormonotherapy (Table 1). The patients
were monitored by periodic medical check-ups, ultrasonographic
and radiological examinations. During the follow-up period, 23
patients (22%) had a recurrent disease and 25 patients (24%) died
of the disease. The mean progression-free survival time was 76
months (range 8–103 months) while the mean overall survival
time was 81 months (range 8–103 months).
Fragments sampled from studied tumours were fixed in 10%
buffered formalin and, then, embedded in paraffin. In every case,
haematoxylin and eosin stained preparations were subjected to
histopathological evaluation by two pathologists. The stage of
tumours was assessed according to TNM classification system
(Sobin and Wittekind, 2002). Tumour grade was estimated
according to Bloom-Richardson in the modification of Elston
and Ellis (Elston and Ellis, 1991) (Table 1).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue was freshly cut (4mm).
The sections were mounted on Superfrost slides (Menzel Gla ¨ser,
Germany), dewaxed with xylene and gradually hydrated. Activity
of endogenous peroxidase was blocked by 5min exposure to 3%
H2O2. Detection of ER and CD24 expression was preceded by
15min exposure of the sections in a microwave oven to boiling
Antigen Retrieval Solution (DakoCytomation, Denmark) at 250W.
Then, immunohistochemical reactions were performed using the
mouse monoclonal (clone 1D5) antibodies to ER (optimaly
prediluted) (DakoCytomation, Denmark), polyclonal rabbit anti-
bodies directed against pS2 (dilution 1:200) (Novocastra, UK),
mouse monoclonal (clone E9) antibodies to MT (dilution 1:100)
(DakoCytomation, Denmark) and the monoclonal (clone SN3)
mouse antibodies detecting CD24 (dilution 1:100) (DakoCytomation,
Denmark). The antibodies were diluted in the Antibody
Diluent, Background Reducing (DakoCytomation, Denmark). The
sections were incubated with an antibody for 1h at room
temperature. Subsequently, incubations were performed with
biotinylated antibodies (15min, room temperature) and with
streptavidin-biotinylated peroxidase complex (15min, room
temperature) (LSAB2, HRP, DakoCytomation, Denmark). DAB
(DakoCytomation, Denmark) was used as a chromogen (7min,
room temperature). All the sections were counterstained with
Meyer’s haematoxylin. In every case, controls were included in
which specific antibody was substituted by the Primary Negative
Control (DakoCytomation, Denmark).
Evaluation of reaction intensity
Intensity of immunohistochemical reactions was evaluated in-
dependently by two pathologists. In equivocal cases, the prepara-
tion was re-evaluated in common. In cases of ER, pS2 and MT
intensity of the immunocytochemical reactions was evaluated
using the semiquantitative scale of the ImmunoReactive Score
(IRS) (Remmele and Stegner, 1987), which took into account
intensity of the colour reaction (0 – no reaction, 1 – weak reaction,
2 – moderate intensity, 3 – intense reaction) as well as proportion
of positive cells (0 – no positive cells, 1 – o10% positive cells, 2 –
10–50% positive cells, 3 – 51–80% positive cells, 4 – 480%
positive cells). The final score represented the product of points
given for individual characters and ranged between 0 and 12. In
evaluation of CD24 expression intensity the scale was employed,
which took into account location of the reaction: the membranous
(CD24m) or cytoplasmic-membranous one (CD24c-m). Cases with
no CD24 expression or the expression in o10% cells were denoted
by ‘0’ while cases with presence of CD24 in more than 10% of
cancer cells were marked by ‘1’ (Surowiak et al, 2005a; Surowiak
et al, 2006).
Table 1 Patient and tumour characteristics
Characteristics No. (%) Log-rank test
All patients 104 (100)
Age (mean 56.2) —
p50 33 (32)
450–60 29 (28)
460 42 (40)
Menopause 0.24
Premenopausal 30 (29)
Postmenopausal 74 (71)
Grade 0.21
2 71 (68)
3 33 (32)
PT 0.74
1 17 (16)
2 86 (83)
4 1 (1)
PN 0.35
0 29 (28)
1 75 (72)
PM —
0 104 (100)
Stage 0.96
I 3 (3)
IIa 40 (38)
IIb 60 (58)
IIIb 1 (1)
Histology —
Ductal 103 (99)
Scirrhous 1 (1)
Therapy
a —
Tamoxifen 70 (67)
Radiotherapy 51 (49)
Cyclophosphamide/methotrexate/5-fluorouracil 28 (27)
Cyclophosphamide/adriamycin/5-fluorouracil 1 (1)
Cyclophosphamide/adriamycin 1 (1)
Progesterone 1 (1)
Letrozol 1 (1)
aSome patients received more than one special treatment.
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Statistical analysis of the results took advantage of Statistica 98 PL
software (Statsoft, Poland). The employed tests included w
2 test
and the Spearman’s rank correlation. Kaplan–Meier’s statistics
and log-rank tests were performed using SPSS software (release
10.0; SPSS Inc., Chicago, IL, USA) to estimate significance of
differences in survival times. The length of survival was defined as
the time between the primary surgical treatment and diagnosis of a
recurrent tumour or death due to the neoplastic disease. We also
performed analyses in the subgroups of the patients – treated with
tamoxifen, treated without tamoxifen, treated with chemotherapy,
treated without chemotherapy, treated with radiotherapy and
treated without radiotherapy.
The multivariate analysis was performed using Cox regression
test.
RESULTS
Immunostaining
In the case of ER the obtained colour reaction was localized in cell
nuclei (Figure 1A). Intensity of the reaction varied in individual
cases. Mean immunoreactivity score amounted to 3.4172.99 s.d.
In the case of pS2, we obtained a colour reaction localised in the
cytoplasm of cancer cells (Figure 1B). The reaction varied in
individual cases. The mean pS2 immunoreactivity score was
2.9572.54 s.d.
In the case of MT, the immunohistochemical reactions yielded a
colour reaction localized in the cytoplasm as well as in cell nuclei
of cancer cells. The reaction varied in individual cases (Figure 1C).
A
B
C
D
Figure 1 Immunohistochemical staining for: (A) oestrogen receptor
alpha (haematoxylin,  400), (B) pS2 (haematoxylin,  200), (C)
metallothionein (haematoxylin,  200) and (D) cytoplasmic-membranous
CD24 (haematoxylin,  400) in the breast cancer specimens.
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Figure 2 Expression of oestrogen receptor alpha (ER), pS2, metallo-
thionein (MT), cytoplasmic-membranous CD24 (CD24c-m) and membra-
nous CD24 (CD24m) vs (A) survival of studied patients and (B)
progression of the disease. The data are grouped according to expression
of ER and: (A) survival and (B) progression.
Table 2 Relationships between studied proteins expressions and various
clinicopathological factors
Characteristics
ER v
2
test
pS2 v
2
test
MT v
2
test
CD24c-m
v
2 test
CD24m
v
2 test
pT 0.0727 0.3948 0.2588 0.5050 0.6863
pN 0.3276 0.2717 0.0234 0.1499 0.7475
Stage 0.5195 0.2338 0.3691 0.2848 0.2620
Grade 0.9952 0.0587 0.1921 0.1972 0.4052
Age 0.7378
a 0.3157
a 0.1067
a 0.7124 0.1698
Menopause status 0.1669 0.0553 0.6263 0.7628 0.1493
Progression 0.6606 0.0568 0.8573 o0.0001 0.7280
Death 0.9670 0.3604 0.9341 o0.0001 0.1558
ER, oestrogen receptor alpha; MT, metallothionein; CD24m, membranous CD24
expression; CD24c-m, cytoplasmic-membranous CD24 expression.
aSpearman’s rank
correlation. Bold signifies Pp0.05.
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reaction was also found in the myoepithelial cells (Figure 1C).
The immunohistochemical reactions using antibodies directed
to CD24 yielded in cancer cells colour reactions of a membranous
localisation (CD24m) or a membranous-cytoplasmatic localisation
(CD24c-m)(Figure 1D), of a variable intensity in individual cases.
In 44 (42%) cases expression of CD24m was disclosed and in 44
(42%) cases the expression manifested the CD24c-m pattern.
Studied protein expression and clinicopathological data
Using the w
2 test relationships were examined between the ER, pS2,
MT, CD24c-m and CD24m expression on one hand and the
variables of the patients, including pT, pN, stage, grade, age
(Spearman’s rank correlation), menopause status, progression and
deaths on the other. The tests proved that progression and deaths
due to breast cancer were significantly more frequent in patients
manifesting expression CD24c-m (Table 2) (Figure 2). Lower pS2
expression was found to be typical for premenopausal patients,
cases of cancer of a higher grade and for patients with progression
of the neoplastic disease (at the verge of statistical significance)
(Table 2) (Figure 2).
Univariate analysis in the entire studied group and in the
subgroups
Univariate analysis demonstrated no relationship between meno-
pausal status, grade, pT, PN and stage of the studied tumours on
one hand and duration of survival of the patients (Table 1).
Differences in overall survival time and progression-free time
were examined between the following groups: (A) patients with no
or lower ER expression (IRS 0–2) and patients with higher ER
expression (IRS 3–12) (Figure 3A and B), (B) patients with of no
or lower pS2 expression (IRS 0–2) and patients with higher pS2
expression (IRS 3–12) (Figure 3C and D), (C) patients with no or
lower MT expression (IRS 0–4) and patients with higher pS2
expression (IRS 6–12) (Figure 4A and B), (D) patients with no or
lower MT expression (IRS 0–6) and patients with higher pS2
expression (IRS 8–12) (Figure 4C and D), (E) patients with no
CD24c-m expression and patients with such expression (Figure 5A
and B) and (F) patients with no CD24m expression and patients
with such expression (Figure 5C and D). The tests demonstrated
that CD24c-m positive cases exhibited a significantly shorter
overall survival time and progression-free time (Figure 5A and B).
In turn, the differences in overall survival time and progression-
free time were examined between patients with favourable
prognostic factors (ER42, pS242, MTo8, CD24c-m negative)
and those with unfavourable prognostic factors (ERo3, PS2o3,
MT46, CD24c-m positive). Despite the very low numerical force
of the compared groups (n¼14) patients with favourable
prognostic factors demonstrated a significantly longer overall
survival time and progression-free survival (Figure 6). None of the
patients with favourable prognostic factors died in the course of
the observation.
We also performed analyses on the subgroups of the patients –
treated with tamoxifen, treated without tamoxifen, treated with
chemotherapy, treated without chemotherapy, treated with radio-
therapy and treated without radiotherapy. In all cases of the
subgroups CD24c-m positive patients were found to exhibit a
significantly shorter overall survival time and progression-free
survival (Table 3). Patients with lower expression of pS2
manifested a significantly shorter progression-free survival in the
subgroup treated with tamoxifen and in the subgroup treated with
radiotherapy (Table 3).
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Figure 3 Kaplan–Meier curves for: (A) overall survival and oestrogen receptor alpha expression, (B) progression-free survival and oestrogen receptor
alpha expression, (C) overall survival and pS2 expression, (D) progression-free survival and pS2 expression.
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Using the Cox regression test relationships were examined between
expression of studied proteins on one hand and overall survival
time and progression-free survival on the other. The relations were
examined both in the entire group of patients and in the subgroup
of patients with various types of postsurgery therapy. The tests
demonstrated that the CD24c-m positive cases manifested
significantly shorter overall survival time and progression-free
survival in the entire group as well as in the subgroups of patients
treated with tamoxifen, treated with radiotherapy, treated without
chemotherapy (Table 4). The patients with a lower pS2 expression
manifested a significantly shorter progression-free survival in the
subgroups of treated with tamoxifen and treated with radiotherapy
(Table 4). CD24m positive patients exhibited a significantly longer
overall survival time in the entire group as well as in the subgroups
treated with tamoxifen and treated without chemotherapy
(Table 4), while a significantly longer progression-free survival
was detected in the subgroups treated with tamoxifen and treated
with radiotherapy (Table 4).
DISCUSSION
In the study, prognostic and predictive values have been examined
of immunohistochemical studies on expression of four distinct
proteins, linked either to sensitivity or to resistance of breast
cancer cells to tamoxifen: oestrogen receptor alpha (ER), pS2
(Fitzgibbons et al, 2000), metallothionein (MT) (Surowiak et al,
2005b) and CD24 (Surowiak et al, 2006) in the group of 104
patients with invasive breast cancer. The relationship has also been
examined between overall survival time and progression-free
survival and the following clinical and pathological variables of
studied patients or tumours: menopausal status, grade, pT, pN and
stage.
Menopausal status, grade, pT, pN and stage belong to the most
important prognostic indices in breast cancer (Goldhirsch et al,
1998; Fitzgibbons et al, 2000). Nevertheless, in this study no
relationship could have been demonstrated between the variables
on one hand and overall survival time and progression-free
survival on the other. This has probably reflected the highly
uniform character of the studied group: 96% of studied patients
carried stage II of the tumour (38% with stage IIa and 58% with
stage IIb).
Determination of ER expression belongs to the routine
histopathological examination in cases of breast cancer. Oestrogen
receptor represents at present the most significant predictive
factors as related to subsequent results of tamoxifen treatment
(Goldhirsch et al, 1998; Yoshinari et al, 1999; Fitzgibbons et al,
2000). In this study, such a prognostic significance of ER
expression could not have been documented using either
univariate analysis or multivariate analysis. Similarly, no signifi-
cant effects of ER expression on survival rates could have been
noted in subgroups of the patients treated with tamoxifen, treated
without tamoxifen, treated with chemotherapy, treated without
chemotherapy, treated with radiotherapy and treated without
radiotherapy. The result might be regarded controversial but in the
years of 1993–1994 ER expression was not yet routinely examined
in the Lower Silesian Centre of Oncology (Wrocław, Poland) and,
therefore, tamoxifen treatment of the patients was not applied in
the targeted manner. In the group not treated with tamoxifen,
mean intensity of ER expression in IRS scale was 3.4172.26 s.d.,
and in the group treated with tamoxifen it amounted to 3.4172.87
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Figure 4 Kaplan–Meier curves for: (A, C) overall survival and metallothionein expression, (B, D) progression-free survival and metallothionein
expression.
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patients (IRS 0–2) and 17 ER positive patients (IRS 3–12). The
group treated with tamoxifen included the same ratio of 35 ER
negative and 35 ER positive patients. The phenomenon seemed to
explain well the lack of relationship between ER expression and
survival rates in the subgroup of tamoxifen-treated patients.
Literature data on prognostic/predictive value of pS2 protein are
inconsistent (Fitzgibbons et al, 2000). In present study, we have
demonstrated that elevated expression of pS2 is typical for
postmenopausal patients with tumours of lower grades, in whom
no progression of the neoplastic process has developed. Univariate
analysis has permitted to show that elevated pS2 expression is
typical of patients with extended progression-free survival in
subgroups treated with tamoxifen and patients treated with
radiotherapy. Similar data have been obtained using multivariate
analysis. The results suggest that elevated expression of pS2
characterizes breast cancer cases of a more benign course. It
should be stressed that no significant relationships of the type have
been obtained for ER and, thus, pS2 seems to represent a strong
favourable prognostic index.
In our previous study, elevated expression of MT was found to
characterize cases resistant to tamoxifen treatment (Surowiak et al,
2005b). In present study, conducted on a higher number of
unselected patients no relationship could have been demonstrated
between MT expression and any clinical or pathological variables
of the patients.
In our earlier studies the cytoplasmic/membranous expression
of CD24 (CD24c-m) was found to represent an unfavourable
prognostic index of breast cancer (Kristiansen et al, 2003c). In the
subsequent studies performed on 60 tamoxifen-treated patients,
we confirmed the unfavourable prognosis associated with CD24c-
m expression (Surowiak et al, 2006). Presence of CD24 in
cytoplasm of tumour cells has been explained by stimulated
synthesis of the protein. Thus, in CD24c-m positive cases most
probably presence of CD24 has been observed in its typical
localisation, in the cell membrane, and the protein has been
transported from endoplasmic reticulum. The observation has
seemed to be confirmed by much higher intensity of the reaction
in CD24c-m positive cases as compared to CD24m positive cases.
In present study, we have corroborated the highly unfavourable
prognostic value of CD24c-m. Using univariate analysis, the
CD24c-m expression has been noted to correlate with shorter
overall survival and progression-free survival in the entire group of
the patients as well as in all the subgroups except of the patients
not treated using radiotherapy. Multivariate analysis has allowed
to confirm the unfavourable prognosis accompanying CD24c-m
expression in the entire group as well as in subgroups of patients
treated with tamoxifen, treated by radiotherapy and not treated
with chemotherapy. The prognostically negative significance of
CD24 expression has been linked to augmented invasive potential
of cells manifesting expression of the protein. CD24 has been
identified as the ligand of P-selectin, the adhesive receptor of
endothelial cells and blood platelets. Most probably, CD24
facilitates intravasation of tumour cells (Kristiansen et al, 2002;
Kristiansen et al, 2003a,b,c; Kristiansen et al, 2004). Recently,
induction of CD24 expression in breast cancer cells was found to
stimulate their proliferation and numerous invasive properties,
like motility and aggressiveness (Baumann et al, 2005). Thus, the
unfavourable significance of CD24 expression in breast cancer cells
may be explained not only by augmented transfer through the
vascular walls but also by the higher proliferative potential of the
cells and their increased ability to invade intercellular matrix. Data
of ours and of other authors suggest that CD24c-m represents one
of the most significant prognostic indices in breast cancer.
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Figure 5 Kaplan–Meier curves for: (A) overall survival and cytoplasmic-membranous CD24 expression, (B) progression-free survival and cytoplasmic-
membranous CD24 expression, (C) overall survival and membranous CD24 expression, (D) progression-free survival and membranous CD24 expression.
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Patients groups
ER (IRS 0–2 vs
3–12) P-value
pS2 (IRS 0–2 vs
3–12) P-value
MT (IRS 0–4 vs
6–12) P-value
CD24c-m
(negative vs
positive) P-value
CD24m (negative vs
positive) P-value
With tamoxifen, n¼70 n¼35 vs n¼35 n¼38 vs n¼32 n¼24 vs n¼46 n¼43 vs n¼27 n¼41 vs n¼29
OS 0.3107 0.2884 0.9408 o0.0001
b 0.1668
PFS 0.9655 0.0442
a 0.6148 o0.0001
b 0.7100
Without tamoxifen, n¼34 n¼17 vs n¼17 n¼19 vs n¼15 n¼13 vs n¼21 n¼17 vs n¼17 n¼19 vs n¼15
OS 0.0739
c 0.7242 0.8852 0.0739
d 0.6986
PFS 0.0739
c 0.7242 0.8852 0.0739
d 0.6725
With radiotherapy, n¼51 n¼30 vs n¼21 n¼27 vs n¼24 n¼15 vs n¼36 n¼28 vs n¼23 n¼30 vs n¼21
OS 0.6239 0.3340 0.5025 o0.0001
b 0.2349
PFS 0.6310 0.0390
a 0.8549 o0.0001
b 0.8650
Without radiotherapy, n¼53 n¼22 vs n¼31 n¼30 vs n¼23 n¼22 vs n¼31 n¼32 vs n¼21 n¼30 vs n¼23
OS 0.4851 0.4622 0.5087 0.1252 0.4398
PFS 0.4732 0.4622 0.5087 0.1314 0.4284
With chemotherapy, n¼28 n¼15 vs n¼13 n¼17 vs n¼11 n¼7 vs n¼21 n¼13 vs n¼15 n¼17 vs n¼11
OS 0.9171 0.6013 0.1320 0.0054
b 0.4830
PFS 0.4950 0.4086 0.3182 0.0023
b 0.8731
Without chemotherapy, n¼76 n¼37 vs n¼39 n¼40 vs n¼36 n¼30 vs n¼46 n¼47 vs n¼29 n¼43 vs n¼33
OS 0.6846 0.3898 0.3600 0.0005
b 0.2104
PFS 0.7277 0.0957 0.2505 0.0007
b 0.6461
ER, oestrogen receptor alpha; MT, metallothionein; OS, overall survival; PFS, progression-free survival. Bold signifies Pp0.05.
aHigher expression correlates with better prognosis.
bNegative expression correlates with better prognosis.
cAll patients with higher expression were alive or without progression.
dAll patients without expression were alive or
without progression.
Table 4 Multivariate analysis of relationships between expression of
studied proteins and survival rates in the entire studied group and in
subgroups of the patients
Patient
groups
ER
P-value
pS2
P-value
MT
P-value
CD24c-m
P-value
CD24m
P-value
Entire group, n¼104
OS 0.349 0.574 0.330 o0.001 0.029
PFS 0.099 0.119 0.412 o0.001 0.149
With tamoxifen, n¼70
OS 0.759 0.155 0.319 o0.001 0.011
PFS 0.298 0.007 0.280 o0.001 0.008
Without tamoxifen, n¼34
OS 0.952 0.701 0.387 0.958 0.348
PFS 0.951 0.700 0.388 0.957 0.278
With radiotherapy, n¼51
OS 0.552 0.455 0.207 o0.001 0.056
PFS 0.160 0.011 0.156 o0.001 0.020
Without radiotherapy, n¼53
OS 0.652 0.646 0.735 0.249 0.563
PFS 0.631 0.649 0.733 0.263 0.545
With chemotherapy, n¼28
OS 0.233 0.690 0.064 0.954 0.638
PFS 0.072 0.664 0.097 0.946 0.901
Without chemotherapy, n¼76
OS 0.891 0.341 0.840 0.001 0.037
PFS 0.697 0.074 0.763 0.001 0.119
ER: oestrogen receptor alpha, MT: metallothionein, OS: overall survival, PFS:
progression-free survival. Bold signifies Pp0.05.
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Figure 6 Kaplan–Meier curves for: (A) overall survival and expression
of favourable or unfavourable prognostic indices, (B) progression-free
survival and expression of favourable or unfavourable prognostic indices.
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expression of CD24 (CD24m) with survival of the patients
(Surowiak et al, 2005a; Surowiak et al, 2006). Using multi-
variate analysis, in present study, we have demonstrated
that CD24m positive cases manifested a significantly longer
overall survival time in the entire group and in the subgroups
treated with tamoxifen and treated without chemotherapy,
and a significantly longer progression-free survival in the
subgroups treated with tamoxifen and treated with radiotherapy.
It should be noted that CD24c-m expression corresponds to
higher intensity of CD24 expression and that the link between
CD24c-m expression and survival rates of the studied patients
was much stronger than that between CD24m expression and
the survival. The favourable prognostic value of CD24m
expression can be explained by the fact that the latter could
have been noted in CD24c-m negative cases. The relationship
indirectly reflects the fact that CD24m positive cases are CD24c-m
negative.
In the study, we have examined also differences in survival rates
between the group of patients with favourable prognostic indices
(ER42, pS242, MTo8, CD24c-m negative) and the group showing
unfavourable prognostic indices (ERo3, PS2o3, MT46, CD24c-m
positive). The result has been surprising: none of the patients with
favourable prognostic indices died. Despite the low numerical force
of the studied subgroup (the total of 14 patients) significant
relationships could have been documented with the overall survival
time and progression-free survival. Thus, examination of the panel
of prognostic indices may significantly augment prognostic
potential in cases of breast cancers and in other tumours.
Summing up, in the present study expression of CD24c-m has
been confirmed to represent a strong unfavourable prognostic
index in breast cancer. The remaining indices either have shown
no relationship with the survival rates of the patients or their
relation with survival was poor. On the other hand, examination of
the entire panel of studied proteins has permitted to select groups
of patients with the extremely good prognosis.
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